Literature DB >> 19554546

Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users.

Tracy Swan, Jen Curry.   

Abstract

Mesh：

Year:  2009        PMID： 19554546     DOI： 10.1002/hep.23077

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.

Authors:  Jason Grebely; Gail V Matthews; Margaret Hellard; David Shaw; Ingrid van Beek; Kathy Petoumenos; Maryam Alavi; Barbara Yeung; Paul S Haber; Andrew R Lloyd; John M Kaldor; Gregory J Dore
Journal:  J Hepatol       Date:  2010-11-23       Impact factor: 25.083

2.  Characteristics and impact of methamphetamine use in patients with chronic hepatitis C.

Authors:  Dana E Riley; Lin Liu; Benjamin Cohen; Shannon Robinson; Erik J Groessl; Samuel B Ho
Journal:  J Addict Med       Date:  2014 Jan-Feb       Impact factor: 3.702

3.  Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Authors:  Evan B Cunningham; Behzad Hajarizadeh; Olav Dalgard; Janaki Amin; Margaret Hellard; Graham R Foster; Philip Bruggmann; Brian Conway; Markus Backmund; Geert Robaeys; Tracy Swan; Philippa S Marks; Sophie Quiene; Tanya L Applegate; Martin Weltman; David Shaw; Adrian Dunlop; Julie Bruneau; Håvard Midgard; Stefan Bourgeois; Maria Christine Thurnheer; Gregory J Dore; Jason Grebely
Journal:  BMC Infect Dis       Date:  2017-06-13       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.